Fresh analysis reveals that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who stop traditional lifestyle programs.
Research printed in a leading medical journal demonstrates that while obese individuals can lose about a fifth of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users buying these drugs must be cognizant of the potential of fast rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
Such speed of recovery means a reversion to original mass in about 18 months.
Analyzing Treatments
The study, which looked at dozens of studies involving thousands of participants, contrasted the effects of the injectable medications with other pills.
The team point out that people who lose weight through diet and exercise usually experience a slower creep back—approximately 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Doctors propose the mode of action of the injections is key to understanding the heightened weight return.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone concentrations several times higher than normal might result in the body to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to appetite is no longer kept in check, making overeating far more likely."
A Chronic Issue?
Medical guidelines advise the injections for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals argue that, given the significant potential of relapse, the therapy is often long-term.
This perspective is supported by drug manufacturers, who say that the results "highlight the long-term nature of obesity," akin to managing conditions like high blood pressure.
User Accounts
Individuals who have stopped the jabs explain a sudden resurgence of hunger.
"It was like a switch that goes on and you become extremely hungry," described an individual.
This difficulty is exacerbated if patients have not established sustainable dietary or behavioural modifications during therapy.
Growing Use
Figures indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Adoption is higher among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, clinicians stress that while these medications are powerful tools for shedding pounds, they are not a standalone solution and lasting health benefits hinges on integrated behavioural changes.
